<?xml version="1.0" encoding="UTF-8"?>
<p id="par0125">Although not a true replicon, the Ebola virus minigenome has been an integral part of Ebola virus basic research and inhibitor discovery. The 2013â€“2016 EBOV outbreak in Sierra Leone, Liberia and Guinea, and the ongoing epidemic in the Democratic Republic of Congo, led to a sharp increase in funding and efforts to develop vaccines and therapeutics against Ebola and related filoviruses. EBOV causes viral haemorrhagic fever with mortality rates of up to 80%, and the virus has to be handled in BSL 4 conditions 
 <xref rid="bib0480" ref-type="bibr">[96]</xref>.
</p>
